236 related articles for article (PubMed ID: 21062352)
21. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression.
Anzo M; Cobb LJ; Hwang DL; Mehta H; Said JW; Yakar S; LeRoith D; Cohen P
Cancer Res; 2008 May; 68(9):3342-9. PubMed ID: 18451161
[TBL] [Abstract][Full Text] [Related]
22. Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model.
Zhang J; Ahn KS; Kim C; Shanmugam MK; Siveen KS; Arfuso F; Samym RP; Deivasigamanim A; Lim LH; Wang L; Goh BC; Kumar AP; Hui KM; Sethi G
Antioxid Redox Signal; 2016 Apr; 24(11):575-89. PubMed ID: 26649526
[TBL] [Abstract][Full Text] [Related]
23. Melatonin MT1 receptor-induced transcriptional up-regulation of p27(Kip1) in prostate cancer antiproliferation is mediated via inhibition of constitutively active nuclear factor kappa B (NF-κB): potential implications on prostate cancer chemoprevention and therapy.
Shiu SY; Leung WY; Tam CW; Liu VW; Yao KM
J Pineal Res; 2013 Jan; 54(1):69-79. PubMed ID: 22856547
[TBL] [Abstract][Full Text] [Related]
24. Melatonin promotes circadian rhythm-induced proliferation through Clock/histone deacetylase 3/c-Myc interaction in mouse adipose tissue.
Liu Z; Gan L; Luo D; Sun C
J Pineal Res; 2017 May; 62(4):. PubMed ID: 27987529
[TBL] [Abstract][Full Text] [Related]
25. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype.
Shiu SY; Law IC; Lau KW; Tam PC; Yip AW; Ng WT
J Pineal Res; 2003 Oct; 35(3):177-82. PubMed ID: 12932201
[TBL] [Abstract][Full Text] [Related]
26. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.
Letsch M; Schally AV; Busto R; Bajo AM; Varga JL
Proc Natl Acad Sci U S A; 2003 Feb; 100(3):1250-5. PubMed ID: 12538852
[TBL] [Abstract][Full Text] [Related]
27. Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis.
Ngo TH; Barnard RJ; Cohen P; Freedland S; Tran C; deGregorio F; Elshimali YI; Heber D; Aronson WJ
Clin Cancer Res; 2003 Jul; 9(7):2734-43. PubMed ID: 12855654
[TBL] [Abstract][Full Text] [Related]
28. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit.
Wang L; Bonorden MJ; Li GX; Lee HJ; Hu H; Zhang Y; Liao JD; Cleary MP; Lü J
Cancer Prev Res (Phila); 2009 May; 2(5):484-95. PubMed ID: 19401524
[TBL] [Abstract][Full Text] [Related]
29. Melatonin as a negative mitogenic hormonal regulator of human prostate epithelial cell growth: potential mechanisms and clinical significance.
Tam CW; Chan KW; Liu VW; Pang B; Yao KM; Shiu SY
J Pineal Res; 2008 Nov; 45(4):403-12. PubMed ID: 18637986
[TBL] [Abstract][Full Text] [Related]
30. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
[TBL] [Abstract][Full Text] [Related]
31. Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice.
Gallardo-Williams MT; Chapin RE; King PE; Moser GJ; Goldsworthy TL; Morrison JP; Maronpot RR
Toxicol Pathol; 2004; 32(1):73-8. PubMed ID: 14713551
[TBL] [Abstract][Full Text] [Related]
32. 15-lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells.
Kelavkar UP; Cohen C
Neoplasia; 2004; 6(1):41-52. PubMed ID: 15068670
[TBL] [Abstract][Full Text] [Related]
33. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
[TBL] [Abstract][Full Text] [Related]
34. Antiproliferative action of melatonin on human prostate cancer LNCaP cells.
Moretti RM; Marelli MM; Maggi R; Dondi D; Motta M; Limonta P
Oncol Rep; 2000; 7(2):347-51. PubMed ID: 10671684
[TBL] [Abstract][Full Text] [Related]
35. Interrelationships between dietary restriction, the IGF-I axis, and expression of vascular endothelial growth factor by prostate adenocarcinoma in rats.
Powolny AA; Wang S; Carlton PS; Hoot DR; Clinton SK
Mol Carcinog; 2008 Jun; 47(6):458-65. PubMed ID: 18058807
[TBL] [Abstract][Full Text] [Related]
36. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
37. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of SIRT1 promotes high glucose-attenuated corneal epithelial wound healing via p53 regulation of the IGFBP3/IGF-1R/AKT pathway.
Wang Y; Zhao X; Shi D; Chen P; Yu Y; Yang L; Xie L
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3806-14. PubMed ID: 23661372
[TBL] [Abstract][Full Text] [Related]
39. SIRT1 Mediates Melatonin's Effects on Microglial Activation in Hypoxia: In Vitro and In Vivo Evidence.
Merlo S; Luaces JP; Spampinato SF; Toro-Urrego N; Caruso GI; D'Amico F; Capani F; Sortino MA
Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32120833
[TBL] [Abstract][Full Text] [Related]
40. Graviola inhibits hypoxia-induced NADPH oxidase activity in prostate cancer cells reducing their proliferation and clonogenicity.
Deep G; Kumar R; Jain AK; Dhar D; Panigrahi GK; Hussain A; Agarwal C; El-Elimat T; Sica VP; Oberlies NH; Agarwal R
Sci Rep; 2016 Mar; 6():23135. PubMed ID: 26979487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
